A Study of the Efficacy, Safety, and Pharmacokinetics of a 36-Week Refill Regimen for the Port Delivery System With Ranibizumab in Patients With Neovascular Age-Related Macular Degeneration (Velodrome)

NCT04657289 · clinicaltrials.gov ↗

PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

451

Enrollment

INDUSTRY

Sponsor class

Conditions

Neovascular Age-related Macular Degeneration (nAMD)

Interventions

DRUG: Ranibizumab
DEVICE: Port Delivery System with Ranibizumab

Sponsor

Hoffmann-La Roche